We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best low volatility stocks to buy according to analysts. While keeping its ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Kissei Pharmaceutical is paying Viridian Therapeutics $70 million upfront for Japanese rights to a pair of thyroid eye ...

This was the stock's third consecutive day of losses.

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and General Motors among those reporting.

The phase 3 FORTITUDE-101 trial, conducted with the support of Zai Lab, has been evaluating bemarituzumab plus mFOLFOX6 ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an analysis of AMGN stock now.

On July 16, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement ...

With a $5 billion investment, the 3,000-employee campus leads biomanufacturing innovation while embracing AI, education and ...